Sedia Biosciences

The Board of Directors of Sedia Biosciences Corporation today announced a series of changes to the Company's executive management team.

Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide

Strategic China partner to aid in access to new international markets for the company’s epidemiological and diagnostic products.

The Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay, a powerful new tool in the global fight against HIV, measures the maturation of the immune response to identify recent HIV infections among those already identified as positive.

Phase I funding of the competitive grant is to develop a novel commercial assay to measure host HIV antibody avidity ("binding ability"), an indicator of antibody maturation, which can be used to determine recent vs. long-term HIV-1 infections.

SEDIA launches its SEDIA™ Dried Blood Spot Controls Pack, a controls and calibrator pack that enables expanded use of the SEDIA™ BED HIV-1 Incidence EIA using dried blood spot specimens for population estimates of HIV-1 incidence.

SEDIA launches its SEDIA(TM) BED HIV-1 Incidence EIA, an enzyme immunoassay based on technology licensed from the US CDC for population estimates of HIV-1 incidence